At a glance
ClinicalIndex Comparison RecordN/ACompleted· 49 enrolled
Drug / intervention
hyperimmune plasmaother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19
Fondazione IRCCS Policlinico San Matteo di Pavia·interventional·Posted Mar 25, 2020·Updated May 28, 2020
In Brief
A clinical study evaluating hyperimmune plasma for COVID-19. Completed, enrolled 49 participants across 2 sites.
Detailed Summary
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become pandemic. To date, no specific treatment has been proven to be effective. Promising results were obtained in China using Hyperimmune plasma from patients recovered from the disease.The investigators plan to treat critical Covid-19 patients with hyperimmune plasma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesItaly
CollaboratorsOSPEDALE CARLO POMA ASST MANTOVA
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartMar 2020
First PostedMar 2020
Primary CompletionApr 2020
Study CompletionMay 2020
TodayJul 2026
First PostedMar 25, 2020
Enrollment StartMar 17, 2020
Primary CompletionApr 28, 2020
Study CompletionMay 7, 2020
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 6.3 years ago
Interventions
hyperimmune plasmaother
administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5